%0 Journal Article
%A Simon, Annika
%A Fritsch, Sebastian
%T Pharmakokinetik: Vilobelimab hemmt C5a bei Intensivpatient*innen mit COVID-19
%J Journal Club AINS
%V 12
%N 04
%@ 2194-9719
%C Stuttgart
%I Thieme
%M FZJ-2023-05177
%P 189 - 191
%D 2023
%< Lim EHT et al. Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients. Intensive Care Med Exp 2023; 11: DOI: 10.1186/s40635-023-00520-8
%F PUB:(DE-HGF)36 ; PUB:(DE-HGF)3 ; PUB:(DE-HGF)16
%9 ReviewBookJournal Article
%R 10.1055/a-2183-8269
%U https://juser.fz-juelich.de/record/1019129